“With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients,” said lead researcher James Gulley, M.D., Ph.D., director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. Gulley and colleagues enrolled 26 patients and assigned them ...
New Brunswick, N.J. – Puberty is a time in a girl’s life considered highly sensitive to stimulation by the hormone estrogen and a critical window during which estrogen exposure could greatly influence the risk of breast cancer later in life. An early onset of puberty also has been consistently shown in studies to increase the ...
Blue Shield of California will stop covering the breast cancer drug Avastin as of Oct. 17. However, it will still pay for the drug if deemed necessary on a case-by-case basis or if members are currently under treatment with the drug, reports the New York Times. The decision makes Blue Shield the largest insurer to ...
Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib* in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib* is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2 (HER2).1 The 1200.89 study ...
The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, ...
